Adhesion molecule-mediated hippo pathway modulates hemangioendothelioma cell behavior

Area of Science:

• Oncology
• Cell Biology
• Vascular Biology

Background:

• Hemangioendotheliomas are intermediate-grade vascular tumors with poorly understood proliferation and apoptosis regulation.
• The Hippo pathway and endothelial cell adhesion molecules are implicated in endothelial cell growth and programmed cell death.

Purpose of the Study:

• To investigate the role of adherens junction molecules, survivin, and the Hippo pathway in hemangioendothelioma (EOMA) cell proliferation and apoptosis.
• To evaluate YM155, an anti-survivin drug, as a potential therapeutic agent for hemangioendotheliomas.

Main Methods:

• Assessed expression of adherens junction molecules (CD31, VE-cadherin), survivin, and Ajuba in EOMA cells.
• Analyzed Hippo pathway signaling, caspase activation, and cell proliferation in EOMA cell cultures.
• Investigated the effects of YM155 and survivin siRNA on EOMA cell characteristics.

Main Results:

• Reduced CD31 and VE-cadherin expression, increased survivin and Ajuba, and decreased Hippo pathway signaling were observed in postconfluent EOMA cells, correlating with increased proliferation.
• YM155 treatment and survivin siRNA transfection induced VE-cadherin, decreased Ajuba, activated the Hippo pathway and caspase, promoted apoptosis, and reduced proliferation.

Conclusions:

• The Hippo pathway plays a critical role in regulating hemangioendothelioma cell proliferation and survival.
• YM155 demonstrates potential as a therapeutic agent for hemangioendotheliomas by modulating survivin and the Hippo pathway.